secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001517022-24-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia discloses preliminary unaudited Auryxia net product revenue for FY2023 in JPM conference presentation
--------------------------------------------------------------------------------

- Presentation at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024 includes preliminary Auryxia revenue.
- Preliminary unaudited net product revenue for Auryxia for fiscal year ended Dec 31, 2023; exact figures not in filing text.
- Investor and analyst meetings coincide with the J.P. Morgan Healthcare Conference starting Jan 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000004/0001517022-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000004/akba-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer